TY - JOUR
T1 - Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists
T2 - Synthesis, pharmacology, and molecular modeling
AU - Frølund, Bente
AU - Jørgensen, Anne T.
AU - Tagmose, Lena
AU - Stensbøl, Tine B.
AU - Vestergaard, Henrik T.
AU - Engblom, Christine
AU - Kristiansen, Uffe
AU - Sanchez, Connie
AU - Krogsgaard-Larsen, Povl
AU - Liljefors, Tommy
PY - 2002/6/6
Y1 - 2002/6/6
N2 - A number of analogues of the low-efficacy partial GABAA agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 5), in which the 4-position of the 3-isoxazolol ring was substituted by different groups, were synthesized and tested as GABAA receptor ligands. Substituents of different size and structural flexibility such as alkyl, phenylalkyl, diphenylalkyl, and naphthylalkyl were explored. Pharmacological characterization of the synthesized compounds was carried out using receptor binding assays and by electrophysiological experiments using whole-cell patch-clamp techniques. Whereas none of these compounds significantly affected GABAB receptor sites or GABA uptake, they did show affinity for the GABAA receptor site. While alkyl or benzyl substitution, compounds 7a-h, provided receptor affinities comparable with that of 5 (Ki = 9.1 μM), diphenylalkyl and naphthylalkyl substitution, as in compounds 7m-t, resulted in a dramatic increase in affinity relative to 5. The 3,3-diphenylpropyl and the 2-naphthylmethyl analogues, compounds 7s and 7m, respectively, showed the highest affinities of the series (Ki = 0.074 μM and Ki = 0.049 μM). In whole-cell patch-clamp recordings from cultured cerebral cortical neurons, all of the tested compounds were able to inhibit the effect of the specific GABAA agonist isoguvacine (1), compounds 7m and 7s showing antagonist potency (IC50 = 0.37 μM and IC50 = 0.02 μM) comparable with or markedly higher than that of the standard GABAA antagonist 4 (IC50 = 0.24 μM). Highly potent convulsant activity was demonstrated in mice with compounds 7m (ED50 = 0.024 μmol/kg) and 7s (ED50 = 0.21 μmol/kg) after intracerebroventricular administration, whereas no effects were found after subcutaneous administration. According to a previously proposed pharmacophore model for GABAA receptor agonists, a receptor cavity in the vicinity of the 4-position of the 3-isoxazolol ring in 4-PIOL exists. A molecular modeling study, based on compounds 7o, m,l,q,s, was performed to explore the dimensions and other properties of the receptor cavity. This study demonstrates the importance of the arylalkyl substituents in 7m and 7s and the considerable dimensions of this proposed receptor cavity.
AB - A number of analogues of the low-efficacy partial GABAA agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 5), in which the 4-position of the 3-isoxazolol ring was substituted by different groups, were synthesized and tested as GABAA receptor ligands. Substituents of different size and structural flexibility such as alkyl, phenylalkyl, diphenylalkyl, and naphthylalkyl were explored. Pharmacological characterization of the synthesized compounds was carried out using receptor binding assays and by electrophysiological experiments using whole-cell patch-clamp techniques. Whereas none of these compounds significantly affected GABAB receptor sites or GABA uptake, they did show affinity for the GABAA receptor site. While alkyl or benzyl substitution, compounds 7a-h, provided receptor affinities comparable with that of 5 (Ki = 9.1 μM), diphenylalkyl and naphthylalkyl substitution, as in compounds 7m-t, resulted in a dramatic increase in affinity relative to 5. The 3,3-diphenylpropyl and the 2-naphthylmethyl analogues, compounds 7s and 7m, respectively, showed the highest affinities of the series (Ki = 0.074 μM and Ki = 0.049 μM). In whole-cell patch-clamp recordings from cultured cerebral cortical neurons, all of the tested compounds were able to inhibit the effect of the specific GABAA agonist isoguvacine (1), compounds 7m and 7s showing antagonist potency (IC50 = 0.37 μM and IC50 = 0.02 μM) comparable with or markedly higher than that of the standard GABAA antagonist 4 (IC50 = 0.24 μM). Highly potent convulsant activity was demonstrated in mice with compounds 7m (ED50 = 0.024 μmol/kg) and 7s (ED50 = 0.21 μmol/kg) after intracerebroventricular administration, whereas no effects were found after subcutaneous administration. According to a previously proposed pharmacophore model for GABAA receptor agonists, a receptor cavity in the vicinity of the 4-position of the 3-isoxazolol ring in 4-PIOL exists. A molecular modeling study, based on compounds 7o, m,l,q,s, was performed to explore the dimensions and other properties of the receptor cavity. This study demonstrates the importance of the arylalkyl substituents in 7m and 7s and the considerable dimensions of this proposed receptor cavity.
UR - http://www.scopus.com/inward/record.url?scp=0037030612&partnerID=8YFLogxK
U2 - 10.1021/jm020027o
DO - 10.1021/jm020027o
M3 - Journal article
C2 - 12036354
AN - SCOPUS:0037030612
VL - 45
SP - 2454
EP - 2468
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
SN - 0022-2623
IS - 12
ER -